メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

市場アクセスへの影響力:潰瘍性大腸炎 (米国)

Market Access Impact: Ulcerative Colitis (US) 2018

発行 FirstWord 商品コード 629539
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.44円で換算しております。
Back to Top
市場アクセスへの影響力:潰瘍性大腸炎 (米国) Market Access Impact: Ulcerative Colitis (US) 2018
出版日: 2018年02月01日 ページ情報: 英文
概要

当レポートでは、米国で潰瘍性大腸炎の治療に従事している医療専門家100名に対するアンケート調査の結果に基づいて、潰瘍性大腸炎の治療薬の利用への影響要因について分析すると共に、主要企業の市場シェア構造や、各社が現在直面している主な障害 (市場アクセスなど) とその原因・影響、取るべき対応策といった情報を取りまとめてお届けいたします。

分析対象製品:潰瘍性大腸炎の主な治療薬

  • Entyvio (ベドリズマブ;武田薬品工業)
  • Humira (アダリムマブ;AbbVie)
  • Renflexis (インフリキシマブ-abda;Merck & Co.)
  • Inflectra (インフリキシマブ-dyyb;Pfizer)
  • Remicade (インフリキシマブ;Janssen Biotech)
  • Simponi (ゴリムマブ;Janssen Biotech)

目次

  • 「市場障壁」とは何か?
  • 当レポートについて
  • 今回の分析について
  • 調査対象のブランド
  • エグゼクティブ・サマリー
目次

Market barriers affect 15% of ulcerative colitis prescriptions. Is your brand losing out?

In the US, where market barriers affect 15% of all ulcerative colitis prescriptions, the top two brands have a significant lead over all other brands. Find out what's driving its share gains, and what your brand can do to level the playing field in Market Access Impact: Ulcerative Colitis (US) [2018].

Based on a survey of 100 gastroenterologists, the report covers 6 major therapies from Takeda, AbbVie, Merck & Co., Pfizer and Janssen Biotech. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways

  • Barriers affect 15% of all prescriptions: But is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • Two brands see significant share increases: 2 brands gain share thanks to barriers, but the top-gaining brand sees a much bigger bump than the brand in 2nd place.
  • One brands sees a significant loss: Despite being prescribed by over 90% of physicians, one brand loses over 4% of their market share because of barriers. Why? And can this be prevented?
  • Eliminating barriers would close the gap at the top: The leading brand relies on other brands losing out. Removing these barriers would have an impact on market share for two leading brands. Are they yours, or one of your competitors?
  • One brand has a perception problem: Nearly 10% of surveyed doctors would not prescribe a specific brand, leaving other brands to capture market share.

Insight into 6 Major Ulcerative Colitis Drugs

  • Entyvio (vedolizumab, Takeda)
  • Humira (adalimumab; AbbVie)
  • Renflexis (infliximab-abda; Merck & Co.)
  • Inflectra (infliximab-dyyb; Pfizer)
  • Remicade (infliximab; Janssen Biotech)
  • Simponi (golimumab; Janssen Biotech)

Exploring Market Access Barriers

Market Access Impact: Ulcerative Colitis (US) [2018] explores key issues affecting Ulcerative Colitis drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based gastroenterologists, chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with Ulcerative Colitis in total in the last month

We conducted the survey between February 6-12, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

Table of Contents

  • 1. What are market barriers?
  • 2. About this report
  • 3. About the survey
  • 4. Brands included in the survey
  • 5. Executive summary
Back to Top